Sumoylation in gene regulation, human disease, and therapeutic action

F1000Prime Reports

Volumn 5, Issue , 2013, Pages

  Yang, Xiang Jiao ^a,b,d   Chiang, Cheng Ming ^c,d  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; DNA BINDING PROTEIN; FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR RECEPTOR; HOMEODOMAIN INTERACTING PROTEIN KINASE 2; KRUPPEL LIKE FACTOR 4; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; MYOCYTE ENHANCER FACTOR 2; OCTAMER TRANSCRIPTION FACTOR 4; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; PROTEIN UBC9; ROSIGLITAZONE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2A; SUMO 1 PROTEIN; SUMO 2 PROTEIN; SUMO 3 PROTEIN; TAMOXIFEN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ELK 1; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BIOGENESIS; BLASTOCYST; CANCER CELL; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CONJUGATION; ENZYME ACTIVITY; GENE CONTROL; GENE DELETION; GENE TARGETING; GENETIC VARIABILITY; HISTONE ACETYLATION; HUMAN; INSULIN SENSITIVITY; LIPID METABOLISM; LOXP SITE; NEDDYLATION; NEOPLASM; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PLURIPOTENT STEM CELL; PROTEIN FUNCTION; PROTEIN METHYLATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STEM CELL; STEM CELL TRANSPLANTATION; SUMOYLATION; TISSUE SPECIFICITY; UBIQUITINATION; ZEBRA FISH;

EID: 84887850498     PISSN: None     EISSN: 20517599     Source Type: Journal    
DOI: 10.12703/P5-45     Document Type: Article

References (65)

1. Matunis MJ, Coutavas E, Blobel G: A novel ubiquitin-like modification modulates the partitioning of the Ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear pore complex. J Cell Biol 1996, 135:1457-70. (Pubitemid 26427644)
2. Mahajan R, Delphin C, Guan T, Gerace L, Melchior F: A small ubiquitin-related polypeptide involved in targeting RanGAP1 to nuclear pore complex protein RanBP2. Cell 1997, 88:97-107. (Pubitemid 27180334)
3. Becker J, Barysch SV, Karaca S, Dittner C, Hsiao H, Berriel Diaz M, Herzig S, Urlaub H, Melchior F: Detecting endogenous SUMO targets in mammalian cells and tissues. Nat Struct Mol Biol 2013, 20:525-31.
4. Geiss-Friedlander R, Melchior F: Concepts in sumoylation: A decade on. Nat Rev Mol Cell Biol 2007, 8:947-56. (Pubitemid 350176509)
5. Hochstrasser M: Origin and function of ubiquitin-like proteins. Nature 2009, 458:422-9.
6. Gareau JR, Lima CD: The SUMOpathway: emerging mechanisms that shape specificity, conjugation and recognition. Nat Rev Mol Cell Biol 2010, 11:861-71.
7. Gill G: SUMO and ubiquitin in the nucleus: different functions, similar mechanisms? Genes Dev 2004, 18:2046-59. (Pubitemid 39166622)
8. Hay RT: SUMO-specific proteases: a twist in the tail. Trends Cell Biol 2007, 17:370-6. (Pubitemid 47375105)
9. Yeh ETH: SUMOylation and De-SUMOylation: wrestling with life's processes. J Biol Chem 2009, 284:8223-7.
10. Yang X: Multisite protein modification and intramolecular signaling. Oncogene 2005, 24:1653-62. (Pubitemid 40461122)
11. Müller S, Hoege C, Pyrowolakis G, Jentsch S: SUMO, ubiquitin's mysterious cousin. Nat Rev Mol Cell Biol 2001, 2:202-10. (Pubitemid 33675745)
12. Seeler J, Dejean A: Nuclear and unclear functions of SUMO. Nat Rev Mol Cell Biol 2003, 4:690-9. (Pubitemid 37082184)
13. Hay RT: SUMO: a history of modification. Mol Cell 2005, 18:1-12. (Pubitemid 40444643)
14. Blomster HA, Hietakangas V, Wu J, Kouvonen P, Hautaniemi S, Sistonen L: Novel proteomics strategy brings insight into the prevalence of SUMO-2 target sites. Mol Cell Proteomics 2009, 8:1382-90.
15. Yang S, Galanis A, Witty J, Sharrocks AD: An extended consensus motif enhances the specificity of substrate modification by SUMO. EMBO J 2006, 25:5083-93. (Pubitemid 44658526)
16. Mohideen F, Capili AD, Bilimoria PM, Yamada T, Bonni A, Lima CD: A molecular basis for phosphorylation-dependent SUMO conjugation by the E2 UBC9. Nat Struct Mol Biol 2009, 16:945-52.
17. Hietakangas V, Anckar J, Blomster HA, Fujimoto M, Palvimo JJ, Nakai A, Sistonen L: PDSM, a motif for phosphorylationdependent SUMO modification. Proc Natl Acad Sci USA 2006, 103:45-50. (Pubitemid 43076102)
18. Shalizi A, Gaudillière B, Yuan Z, Stegmüller J, Shirogane T, Ge Q, Tan Y, Schulman B, Harper JW, Bonni A: A calcium-regulated MEF2 sumoylation switch controls postsynaptic differentiation. Science 2006, 311:1012-7. (Pubitemid 43271730)
19. Grégoire S, Tremblay AM, Xiao L, Yang Q, Ma K, Nie J, Mao Z, Wu Z, Giguère V, Yang X: Control of MEF2 transcriptional activity by coordinated phosphorylation and sumoylation. J Biol Chem 2006, 281:4423-33. (Pubitemid 43847874)
20. Tremblay AM, Wilson BJ, Yang X, Giguère V: Phosphorylationdependent sumoylation regulates estrogen-related receptoralpha and -gamma transcriptional activity through a synergy control motif. Mol Endocrinol 2008, 22:570-84. (Pubitemid 351397786)
21. Yang X, Grégoire S: A recurrent phospho-sumoyl switch in transcriptional repression and beyond. Mol Cell 2006, 23:779-86. (Pubitemid 44344522)
22. Matic I, Schimmel J, Hendriks IA, van Santen MA, van de Rijke F, van Dam H, Gnad F, Mann M, Vertegaal ACO: Site-specific identification of SUMO-2 targets in cells reveals an inverted SUMOylation motif and a hydrophobic cluster SUMOylation motif. Mol Cell 2010, 39:641-52.
23. Hsieh Y, Kuo H, Chang C, Naik MT, Liao P, Ho C, Huang T, Jeng J, Hsu P, Tsai M, Huang T, Shih H: Ubc9 acetylation modulates distinct SUMO target modification and hypoxia response. EMBO J 2013, 32:791-804.
24. Klug H, Xaver M, Chaugule VK, Koidl S, Mittler G, Klein F, Pichler A: Ubc9 sumoylation controls SUMOchain formation and meiotic synapsis in Saccharomyces cerevisiae. Mol Cell 2013, 50:625-36.
25. Li Q, Yang S, Maeda Y, Sladek FM, Sharrocks AD, Martins-Green M: MAP kinase phosphorylation-dependent activation of Elk-1 leads to activation of the co-activator p300. EMBO J 2003, 22:281-91. (Pubitemid 36119434)
26. Kruse J, Gu W: SnapShot: p53 posttranslational modifications. Cell 2008, 133:930-30.e1.
27. Wu S, Chiang C: p53 sumoylation: mechanistic insights from reconstitution studies. Epigenetics 2009, 4:445-51.
28. Vousden KH, Prives C: Blinded by the Light: The Growing Complexity of p53. Cell 2009, 137:413-31.
29. Wu S, Lee A, Lai H, Zhang H, Chiang C: Phospho switch triggers Brd4 chromatin binding and activator recruitment for genespecific targeting. Mol Cell 2013, 49:843-57.
30. Bennett RL, Pan Y, Christian J, Hui T, May WS: The RAX/PACTPKR stress response pathway promotes p53 sumoylation and activation, leading to G1 arrest. Cell Cycle 2012, 11:407-17.
31. Wu S, Chiang C: Crosstalk between sumoylation and acetylation regulates p53-dependent chromatin transcription and DNA binding. EMBO J 2009, 28:1246-59.
32. Tatham MH, Geoffroy M, Shen L, Plechanovova A, Hattersley N, Jaffray EG, Palvimo JJ, Hay RT: RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol 2008, 10:538-46. (Pubitemid 351627373)
33. Lallemand-Breitenbach V, Jeanne M, Benhenda S, Nasr R, Lei M, Peres L, Zhou J, Zhu J, Raught B, Thé H de: Arsenic degrades PML or PMLRARalpha through a SUMO-triggered RNF4/ubiquitinmediated pathway. Nat Cell Biol 2008, 10:547-55. (Pubitemid 351627374)
34. Guo Z, Kanjanapangka J, Liu N, Liu S, Liu C, Wu Z, Wang Y, Loh T, Kowolik C, Jamsen J, Zhou M, Truong K, Chen Y, Zheng L, Shen B: Sequential posttranslational modifications program FEN1 degradation during cell-cycle progression. Mol Cell 2012, 47:444-56.
35. La Vega L de, Grishina I, Moreno R, Krüger M, Braun T, Schmitz ML: A redox-regulated SUMO/acetylation switch of HIPK2 controls the survival threshold to oxidative stress. Mol Cell 2012, 46:472-83.
36. González-Santamaría J, Campagna M, Ortega-Molina A, Marcos-Villar L, La Cruz-Herrera CF de, González D, Gallego P, Lopitz-Otsoa F, Esteban M, Rodríguez MS, Serrano M, Rivas C: Regulation of the tumor suppressor PTEN by SUMO. Cell Death Dis 2012, 3:e393.
37. Bassi C, Ho J, Srikumar T, Dowling RJO, Gorrini C, Miller SJ, Mak TW, Neel BG, Raught B, Stambolic V: Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress. Science 2013, 341:395-9.
38. Tsao H, Chin L, Garraway LA, Fisher DE: Melanoma: from mutations to medicine. Genes Dev 2012, 26:1131-55.
39. Murakami H, Arnheiter H: Sumoylation modulates transcriptional activity of MITF in a promoter-specific manner. Pigment Cell Res 2005, 18:265-77. (Pubitemid 41032886)
40. Miller AJ, Levy C, Davis IJ, Razin E, Fisher DE: Sumoylation of MITF and its related family members TFE3 and TFEB. J Biol Chem 2005, 280:146-55. (Pubitemid 40164975)
41. Yokoyama S, Woods SL, Boyle GM, Aoude LG, MacGregor S, Zismann V, Gartside M, Cust AE, Haq R, Harland M, Taylor JC, Duffy DL, Holohan K, Dutton-Regester K, Palmer JM, Bonazzi V, Stark MS, Symmons J, Law MH, Schmidt C, Lanagan C, O'Connor L, Holland EA, Schmid H, Maskiell JA, Jetann J, Ferguson M, Jenkins MA, Kefford RF, Giles GG, et al.: A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 2011, 480:99-103.
42. Bertolotto C, Lesueur F, Giuliano S, Strub T, de LichyM, BilleK,Dessen P, d'Hayer B, Mohamdi H, Remenieras A, Maubec E, La de Fouchardière A, Molinié V, Vabres P, Dalle S, Poulalhon N, Martin-Denavit T, Thomas L, Andry-Benzaquen P, Dupin N, Boitier F, Rossi A, Perrot J, Labeille B, Robert C, Escudier B, Caron O, Brugières L, Saule S, Gardie B, et al.: A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 2011, 480:94-8.
43. Sturm RA, Fox C, McClenahan P, Jagirdar K, Ibarrola-Villava M, Banan P, Abbott NC, Ribas G, Gabrielli B, Duffy DL, Soyer HP: Phenotypic Characterization of Nevus and Tumor Patterns in MITF E318K Mutation Carrier Melanoma Patients. J Invest Dermatol 2013.
44. Ghiorzo P, Pastorino L, Queirolo P, Bruno W, Tibiletti MG, Nasti S, Andreotti V, Paillerets BB, Bianchi Scarrà G: Prevalence of the E318K MITF germline mutation in Italian melanoma patients: associations with histological subtypes and family cancer history. Pigment Cell Melanoma Res 2013, 26:259-62.
45. Kessler JD, Kahle KT, Sun T, Meerbrey KL, Schlabach MR, Schmitt EM, Skinner SO, Xu Q, Li MZ, Hartman ZC, Rao M, Yu P, Dominguez- Vidana R, Liang AC, Solimini NL, Bernardi RJ, Yu B, Hsu T, Golding I, Luo J, Osborne CK, Creighton CJ, Hilsenbeck SG, Schiff R, Shaw CA, Elledge SJ, Westbrook TF: A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science 2012, 335:348-53.
46. Kho C, Lee A, Jeong D, Oh JG, Chaanine AH, Kizana E, Park WJ, Hajjar RJ: SUMO1-dependent modulation of SERCA2a in heart failure. Nature 2011, 477:601-5.
47. Ribet D, Hamon M, Gouin E, Nahori M, Impens F, Neyret-Kahn H, Gevaert K, Vandekerckhove J, Dejean A, Cossart P: Listeria monocytogenes impairs SUMOylation for efficient infection. Nature 2010, 464:1192-5.
48. Everett RD, Boutell C, Hale BG: Interplay between viruses and host sumoylation pathways. Nat Rev Microbiol 2013, 11:400-11.
49. Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, Evans RM: PPARg signaling and metabolism: the good, the bad and the future. Nat Med 2013, 19:557-66.
50. Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, Perissi V, Rose DW, Willson TM, Rosenfeld MG, Glass CK: A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005, 437:759-63. (Pubitemid 41486547)
51. Yamashita D, Yamaguchi T, Shimizu M, Nakata N, Hirose F, Osumi T: The transactivating function of peroxisome proliferatoractivated receptor gamma is negatively regulated by SUMO conjugation in the amino-terminal domain. Genes Cells 2004, 9:1017-29. (Pubitemid 39467975)
52. Floyd ZE, Stephens JM: Control of peroxisome proliferatoractivated receptor gamma2 stability and activity by SUMOylation. Obes Res 2004, 12:921-8. (Pubitemid 41202392)
53. Ohshima T, Koga H, Shimotohno K: Transcriptional activity of peroxisome proliferator-activated receptor gamma is modulated by SUMO-1 modification. J Biol Chem 2004, 279: 29551-7. (Pubitemid 38915836)
54. Dutchak PA, Katafuchi T, Bookout AL, Choi JH, Yu RT, Mangelsdorf DJ, Kliewer SA: Fibroblast growth factor-21 regulates PPARg activity and the antidiabetic actions of thiazolidinediones. Cell 2012, 148:556-67.
55. Nacerddine K, Lehembre F, Bhaumik M, Artus J, Cohen-Tannoudji M, Babinet C, Pandolfi PP, Dejean A: The SUMO pathway is essential for nuclear integrity and chromosome segregation in mice. Dev Cell 2005, 9:769-79. (Pubitemid 41724105)
56. Nowak M, Hammerschmidt M: Ubc9 regulates mitosis and cell survival during zebrafish development. Mol Biol Cell 2006, 17:5324-36. (Pubitemid 44907372)
57. Demarque MD, Nacerddine K, Neyret-Kahn H, Andrieux A, Danenberg E, Jouvion G, Bomme P, Hamard G, Romagnolo B, Terris B, Cumano A, Barker N, Clevers H, Dejean A: Sumoylation by Ubc9 regulates the stem cell compartment and structure and function of the intestinal epithelium in mice. Gastroenterology 2011, 140:286-96.
58. Takahashi K, Yamanaka S: Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-76. (Pubitemid 44233629)
59. Kawai-Kowase K, Ohshima T, Matsui H, Tanaka T, Shimizu T, Iso T, Arai M, Owens GK, Kurabayashi M: PIAS1 mediates TGFbetainduced SM alpha-actin gene expression through inhibition of KLF4 function-expression by protein sumoylation. Arterioscler Thromb Vasc Biol 2009, 29:99-106.
60. Tsuruzoe S, Ishihara K, Uchimura Y, Watanabe S, Sekita Y, Aoto T, Saitoh H, Yuasa Y, Niwa H, Kawasuji M, Baba H, Nakao M: Inhibition of DNA binding of Sox2 by the SUMO conjugation. Biochem Biophys Res Commun 2006, 351:920-6. (Pubitemid 44715874)
61. Wei F, Schöler HR, Atchison ML: Sumoylation of Oct4 enhances its stability, DNA binding, and transactivation. J Biol Chem 2007, 282:21551-60. (Pubitemid 47099909)
62. Tolkunova E, Malashicheva A, Parfenov VN, Sustmann C, Grosschedl R, Tomilin A: PIAS proteins as repressors of Oct4 function. J Mol Biol 2007, 374:1200-12. (Pubitemid 350122540)
63. Tahmasebi S, Ghorbani M, Savage P, Yan K, Gocevski G, Xiao L, You L, Yang X: Sumoylation of Krüppel-like factor 4 inhibits pluripotency induction but promotes adipocyte differentiation. J Biol Chem 2013, 288:12791-804.
64. Heng JD, Feng B, Han J, Jiang J, Kraus P, Ng J, Orlov YL, Huss M, Yang L, Lufkin T, Lim B, Ng H: The nuclear receptor Nr5a2 can replace Oct4 in the reprogramming of murine somatic cells to pluripotent cells. Cell Stem Cell 2010, 6:167-74.
65. Feng B, Jiang J, Kraus P, Ng J, Heng JD, Chan Y, Yaw L, Zhang W, Loh Y, Han J, Vega VB, Cacheux-Rataboul V, Lim B, Lufkin T, Ng H: Reprogramming of fibroblasts into induced pluripotent stem cells with orphan nuclear receptor Esrrb. Nat Cell Biol 2009, 11:197-203.